Sàbat M, Kolle L, Soriano G, Ortiz J, Pamplona J, Novella M T, Villanueva C, Sainz S, Torras J, Balanzó J, Guarner C
Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Am J Gastroenterol. 1998 Dec;93(12):2457-62. doi: 10.1111/j.1572-0241.1998.00704.x.
Selective intestinal decontamination with norfloxacin is useful in the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding. However, bleeding cirrhotic patients with ascites, encephalopathy, or shock are at high risk to develop bacterial infections in spite of prophylactic norfloxacin. The aim of this study was to assess whether the addition of intravenous ceftriaxone could improve the efficacy of prophylaxis with norfloxacin in these patients.
Fifty-six cirrhotic patients with gastrointestinal hemorrhage and ascites, encephalopathy, or shock were randomized into two groups: Group 1 (n = 28) received oral norfloxacin 400 mg/12 h for 7 days, and group 2 (n = 28) received norfloxacin plus intravenous ceftriaxone 2 g daily during the first 3 days of admission.
Ten patients were excluded because of community-acquired infection, surgery, or death within the first 24 h. The incidence of bacterial infections during hospitalization was 18.1% in group 1 and 12.5% in group 2 (p = NS). The incidence of severe infections (spontaneous bacterial peritonitis, bacteremia, or pneumonia) was also similar in both groups: 9% in group 1 versus 8.3% in group 2 (p = NS). There were no statistical differences between the two groups with respect to duration of hospitalization or mortality. The cost of antibiotic therapy (including prophylaxis and treatment of infections) was significantly higher in group 2.
These results suggest that the addition of intravenous ceftriaxone during the first 3 days of hospitalization does not improve the cost-efficacy of oral norfloxacin in the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding and high risk of infection.
诺氟沙星选择性肠道去污有助于预防肝硬化合并胃肠道出血患者的细菌感染。然而,尽管使用了预防性诺氟沙星,合并腹水、肝性脑病或休克的出血性肝硬化患者发生细菌感染的风险仍很高。本研究的目的是评估加用静脉注射头孢曲松是否能提高诺氟沙星对这些患者的预防效果。
56例肝硬化合并胃肠道出血且伴有腹水、肝性脑病或休克的患者被随机分为两组:第1组(n = 28)口服诺氟沙星400 mg/12小时,共7天;第2组(n = 28)在入院的头3天接受诺氟沙星加静脉注射头孢曲松2 g/天。
10例患者因社区获得性感染、手术或在最初24小时内死亡而被排除。住院期间细菌感染的发生率在第1组为18.1%,在第2组为12.5%(p = 无显著性差异)。两组严重感染(自发性细菌性腹膜炎、菌血症或肺炎)的发生率也相似:第1组为9%,第2组为8.3%(p = 无显著性差异)。两组在住院时间或死亡率方面无统计学差异。第2组抗生素治疗的费用(包括感染的预防和治疗)显著更高。
这些结果表明,在住院的头3天加用静脉注射头孢曲松并不能提高口服诺氟沙星预防肝硬化合并胃肠道出血且感染风险高的患者细菌感染的成本效益。